Breaking News
March 18, 2019 - Taking painkillers during pregnancy is not responsible for asthma risk in children, study shows
March 18, 2019 - Prediagnosis Psychiatric Care Linked to Worse Cancer Mortality
March 18, 2019 - Paris hospital halts stool study after donor deluge
March 18, 2019 - Partial oral antibiotic therapy shows efficacy and safety in patients with infectious endocarditis
March 18, 2019 - Olympus improves access to science education through BioBus collaboration
March 18, 2019 - Depression screening does not improve quality of life in heart attack patients
March 18, 2019 - Echocardiography may aid in patient selection for TMVR
March 18, 2019 - Are ‘Inactive’ Ingredients in Your Drugs Really So Harmless?
March 18, 2019 - Scientists tackle rare retinal disease in unique research project
March 18, 2019 - Death By A Thousand Clicks
March 18, 2019 - Absorbable, antibiotic-eluting envelope can reduce rate of cardiac device infections
March 18, 2019 - Hormonal treatment associated with depression in men with prostate cancer
March 18, 2019 - Porvair Sciences launches reinforced 96-well deep round microplate
March 18, 2019 - Simplified catheter ablation could slash waiting lists for atrial fibrillation patients
March 18, 2019 - BFR therapy as part of rehabilitation following ACL surgery may slow bone loss
March 18, 2019 - A human model to test implants for cataract surgery
March 18, 2019 - New risk adjustment model could reduce financial penalty for safety net hospitals
March 18, 2019 - NHS cancer patients’ wait to start treatment worrying
March 18, 2019 - Inventiva Announces Results from Phase IIb Clinical Trial with Lanifibranor in Systemic Sclerosis
March 18, 2019 - Cologuard
March 18, 2019 - Researchers find evidence of prenatal environment tuning genomic imprinting
March 18, 2019 - Dolomite Bio launches novel Nadia product family for single-cell research
March 18, 2019 - Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
March 18, 2019 - Excessive gestational weight gain tied to maternal morbidity
March 18, 2019 - RCEM issues position statement on metrics to supplement four-hour standard target
March 17, 2019 - Noncontrast Brain MRI Effective for Monitoring Multiple Sclerosis
March 17, 2019 - Brain region plays key role in regulation of parenting behavior, study finds
March 17, 2019 - Natural speed limit on DNA replication sets pace for life’s first steps
March 17, 2019 - New research reveals overlooked impact of herbicide glyphosate on the environment
March 17, 2019 - Molecular patterns could help predict relapse risk in breast cancer patients
March 17, 2019 - Study confirms sensitivity of microbiological cultures for detecting cholera
March 17, 2019 - Scientists Spot Clues to Predicting Breast Cancer’s Return
March 17, 2019 - Scientists identify gene that keeps PTSD-like behavior at bay in female mice
March 17, 2019 - New method would allow doctors to detect earliest stages of cancers in the lymph nodes
March 17, 2019 - Cholesterol protein discovery raises hope for smarter drugs
March 17, 2019 - New insect medium delivers high viable cell density growth and protein yield
March 17, 2019 - Opioid crisis brings concerns about heart dangers
March 17, 2019 - Resistance Training May Prevent Type 2 Diabetes Progression
March 17, 2019 - Bioluminescence sensors make new approaches to drug discovery possible
March 17, 2019 - New FDA Rules Aim to Keep Kids From Flavored E-Cigarettes
March 17, 2019 - Vitamin B3 analogue boosts production of blood cells
March 17, 2019 - Government cuts to stop smoking services have detrimental impact on public health
March 17, 2019 - Common tool to assess potential adoptive parents lags behind societal changes
March 17, 2019 - Patients’ own cells could be the key to treating Crohn’s disease
March 17, 2019 - Diagnostic delays common in inflammatory bowel disease
March 17, 2019 - Study uncovers dramatic differences in the brains of Hispanics with dementia
March 17, 2019 - Study describes epigenetic loss that changes how cells obtain energy from cancer
March 16, 2019 - Active Bathing in Non-ICU Setting Does Not Cut Infections
March 16, 2019 - How the immune system maintains a healthy gut microbiota
March 16, 2019 - Bacteria ‘trap’ could help in the fight against antimicrobial resistance
March 16, 2019 - Hospital work environment associated with all EHR usability outcomes
March 16, 2019 - Study unravels mystery behind how the brain encodes time when forming long-term memories
March 16, 2019 - Light physical activity may lower risk of cardiovascular disease in older women
March 16, 2019 - USP15 enzyme could potentially lead to new treatments for breast, pancreatic cancer
March 16, 2019 - After Chinese Infant Gene-Editing Scandal, U.S. Health Officials Join Call for a Ban
March 16, 2019 - PACS1 syndrome – Genetics Home Reference
March 16, 2019 - Researchers discover an unexpected organization of antimicrobial molecules that amplifies immune response
March 16, 2019 - With New Study, Era of Open-Heart Surgery for Aortic Stenosis May be Ending
March 16, 2019 - Dolomite Bio introduces high throughput sNuc-Seq protocol for its Nadia Instrument
March 16, 2019 - New course prepares materials scientists for biomedical testing
March 16, 2019 - Finding clues to a functional HIV cure
March 16, 2019 - People with chronic periodontitis have higher risk for dementia
March 16, 2019 - Few heart care recommendations are based on rigorous study
March 16, 2019 - Colorectal cancer diagnosed at early age is distinct from that in older patients
March 16, 2019 - Researchers use MRI and AI techniques at birth to predict cognitive development at age 2
March 16, 2019 - Discarding information from the brain linked to more mental effort, finds study
March 16, 2019 - OTA International supplement provides current snapshot and forward look at global trauma systems
March 16, 2019 - NIH trial to track outcomes of liver transplantation from HIV+ donors to HIV+ recipients
March 16, 2019 - Apple Heart Study shows how wearable technology can help detect heart problem
March 16, 2019 - Researchers determine factors that cause stress development in the human body
March 16, 2019 - Elderly Men Undertreated for Osteoporosis
March 16, 2019 - People with chronic pain are coping with the help of Pinterest, new study reveals
March 16, 2019 - New study could reveal the complex interaction between languages and human beings who use them
March 16, 2019 - Tufts engineers develop new tool to identify metabolic signatures linked to disease
March 16, 2019 - New proteomics-based test could aid in early detection of ovarian cancer
March 16, 2019 - New research opens possibility of using sperm taken from testicles to overcome infertility
March 16, 2019 - Scientists find new proof that narcolepsy is an autoimmune disease
March 16, 2019 - FDA OKs a New Generic of the Blood Pressure Drug Valsartan to Ease Shortage Due to Recalls
March 16, 2019 - Eliminating smoking and obesity could affect racial health disparities
March 16, 2019 - Wearable tracking device achieves higher accuracy in position tracking using thermal sensors
New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

image_pdfDownload PDFimage_print

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. (NYSE: ANTM) and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes – one of the nation’s fastest growing chronic diseases.

The randomized Ozempic pragmatic trial, “Long-term comparative effectiveness of once weekly SEmaglutide versus standard of care in a real world adult US population with type 2 diabetes – a randomized PRAgmatic clinical trial,” or SEPRA, will compare the long-term effectiveness of Ozempic to potentially 40 other medications among 2,250 adult consumers with Type 2 diabetes. The trial aims to learn whether Ozempic leads to better outcomes or impacts the need for health services compared to other FDA-approved drugs to treat diabetes.

“Because the SEPRA trial seeks to find out what happens with people using anti-diabetic therapies after FDA approval, it may be of greater interest to more people and doctors than a standard randomized clinical trial, which requires intense monitoring and coaching of consumers to take medications,” said study clinical advisor Dr. John Buse, director, Diabetes Center at the University of North Carolina School of Medicine. “This trial will be relying on how doctors work with their patients in the real world with little outside guidance.”

HealthCore researchers will follow consumers participating in the trial for two years from when they enroll to determine whether they met their HbA1C goals in comparison to those treated with drugs other than Ozempic, as well as determine whether consumers using these drugs consume fewer health services, such as ER visits and hospitalizations. The study will also compare body weight change, patient-reported outcomes such as quality of life, hypoglycemia rates, and adherence and persistence with treatment and safety.

“We are proud to be a leader in the field of pragmatic study research,” said SEPRA lead researcher Vince Willey, HealthCore principal scientist. “We believe this type of collaboration and acceleration of research demonstrated in SEPRA will help in identifying the therapies with the best outcomes for a large and diverse population.”

“We strongly believe in the clinical value of this medication, and are excited to learn more about its real-world use in adults with type 2 diabetes,” said Todd Hobbs, chief medical officer, Novo Nordisk Inc. “We invest in studies like SEPRA because payers and physicians want to know how to achieve high quality care that’s cost effective.”

GLP-1 receptor agonists are one of the newest drug classes for treating Type 2 diabetes with an estimated 1.3 million Americans currently filling prescriptions for them. While studies used for FDA approval have demonstrated the efficacy of the drugs in a clinical trial setting, there is limited evidence about their actual benefit in a real-world environment.

To access information on the trial, care providers and consumers can email [email protected]

There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis, in patients treated with GLP-1 receptor agonists. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of Ozempic® in patients reporting severe adverse gastrointestinal reactions.

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with GLP-1 receptor agonists. If hypersensitivity reactions occur, discontinue use of Ozempic®; treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist.

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Ozempic®.

The most common adverse reactions, reported in ≥5% of patients treated with Ozempic® are nausea, vomiting, diarrhea, abdominal pain, and constipation.

The risk of hypoglycemia may be lowered by a reduction in the dose of the secretagogue or insulin. Ozempic® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications, so caution should be exercised.

There are limited data with semaglutide use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. Discontinue Ozempic® in women at least 2 months before a planned pregnancy due to the long washout period for semaglutide.

Source:

https://www.healthcore.com/

Tagged with:

About author

Related Articles